<DOC>
	<DOCNO>NCT02291991</DOCNO>
	<brief_summary>This randomize , placebo control , single dose study assess safety , tolerability , pharmacokinetics pharmacodynamics GX-E2 healthy male subject .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics/Pharmacodynamics GX-E2 Healthy Subjects</brief_title>
	<detailed_description>The purpose study investigate safety , tolerability pharmacokinetics GX-E2 give single dose ( GX-E2 8 ug/kg ) healthy male subject . Additionally , Immunogenecity evaluate investigate antibody production .</detailed_description>
	<criteria>Written inform consent Male subject 20 55 year old Adequate body weigth BMI ( 19 ≤ BMI ≤ 27 , 60.0kg ≤ body weigth ≤ 90.0kg ) The subject n't clinically significant abnormal laboratory value and/or clinically significant unstable medical disease history . Are eligible study hemoglobin data ( 12.0g/dL ≤ Hb ≤ 16.5g/dL ) ( Data check per 2 week within 28 day ) Adequate transferrin saturation , serum ferritin within 28 day Adequate folate within 28 day Adequate vitamin B12 within 28 day Adequate WBC count ( ≥ 3.0 X 1000 µL ) Adequate PLT count ( ≥ 140 X 1000 µL ) nonsmoker smoker smoke 10 cigarette day The subject clinically significant abnormal allergy include medical allergy . The subject evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , neurological , immunodeficiency , pulmonary , disorder disease Subject previous experience i.v . administration EPO , darbepoetin , EPO supply protein , immunoglobulin iron drug Subject hypersensitivity EPO , darbepoetin supplementary iron drug Subject condition hemoglobinopathy ( e.g . sicklecell disease thalassemia ) Subject show follow systolic diastolic parameter sit position 3 minute rest : low 90 mmHg high 140mmHg systolic blood pressure low 50 mmHg high 90mmHg diastolic blood pressure Subject chronic uncontrollable symptom inflammatory disease ( e.g . rheumatoid arthritis systemic lupous erythematousus ) Subject exceed level Creactive protein 4 mg/dL 2 week IP administration History drug prior screen urine drug test positive ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids ) Subject administer prescribed drug oriental herbal medicine 2 week IP administration , administer general pharmaceutical vitamin 1 week IP administration Subject enrol clinical trial IP approve drug within 8 week IP administration Subject history fever body temperature 38°C week IP administration History epileptic convulsion within 6 month Subject positive HIV , HBsAg , HCV antibody test Subject regular alcohol consumption 21 unit , unable quit drinking period clinical trial Subject donate lose 400mL blood within 8 week prior first dose Subject treat investigational product . Subject long length spleen 16cm via upper abdominal ultrasound screen Subject consider inappropriate participation Investigator base various lab result Subject plan pregnant least unable apply authorize contraceptive method ( e.g . sterilization operation , use contraceptive device )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Immunogenecity</keyword>
</DOC>